History

Our experience, your guarantee

Hyaltech was founded as a research & development company in 1981 focused on the development of continuous fermentation processes including production of HA for medical applications. Hyaltech has leveraged its HA biotechnology platform to develope and manufacture high quality  HA medical solutions that offer benefits to patients, meet the needs of healthcare providers and sustain the business of our partners.

Timeline of Events:

1981
Foundation of Fermentech

1995
Fermentech receives CE-mark approval for Ophthalin, an ophthalmic viscosurgical device, OVD,  for cataract surgery.

1996
Fermentech receives CE-mark approval for Ophthalin plus, an OVD for cataract surgery.

1999
Fermentech receives CE-mark approval for Fermathron, a viscosupplement for knee osteoarthritis.

2000
Fermentech merged with Swedish IVF Science company becoming Vitrolife UK

2002
Acquisition of Vitrolife UK by Ioltech SA, becoming Hyaltech Ltd.
Hyaltech receives CE-mark approvl for VISTHESIA-the first and only OVD with ancillary lidocaine. Market launch of VISTHESIA by Ioltech SA.

2004
Acquisition of Ioltech SA/Hyaltech Ltd by Carl Zeiss Meditec AG.
Hyaltech receives CE-mark for rejuvenation medical device with lidocaine-Zetavisc-L
Hyaltech receives CE-mark for Sigmavisc for endoscopic mucosal resection

2005
Hyaltech receives CE-mark for TWINVISC-two OVD\'s-in a double chamber syringe. Market launch of TWINVISC by Ioltech SA/Carl Zeiss Meditec AG

2007
Hyaltech receives CE-mark for viscosupplement, for pain relief in case of ankle sprain and elbow injury

2008
Hyaltech receives CE-mark for a double chamber viscosupplement for pain relief in knee osteoarthritis.

2009
Hyaltech moved to  Starlaw Business Park in Livingston to increase capacity and meet market demands.
Hyaltech receives CE-mark for Fermathron plus, a high molecular viscosuppment for the treatment of knee osteoarthritis.

2010
Hyaltech receives CE-mark for Fermathron S, a single injection viscosupplement for knee osteoarthritis